ASH

This week, a focus on key results from the American Society of Hematology meeting: Jaypirca headed for the front line; Kite’s Anito-cel in multiple myeloma; next-generation CAR-T approaches; Kelownia’s early in vivo CAR-T data; and Novartis’s ianalumab’s potential in ITP.

The drugmaker presented multiple posters of data for the recently reapproved BCMA-targeting antibody-drug conjugate at the just concluded ASH meeting.

Lupeng's BTK inhibitor rocbrutinib has shown an 80.0% ORR in a Phase I trial in patients who had received a covalent or non-covalent BTK inhibitor plus BCL-2 inhibitor, setting the stage for a comparative trial, possibly with Jaypirca.

J&J's late-breaking Phase III MajesTEC-3 data at the American Society of Hematology meeting highlighted curative potential for the bispecific T-cell engager in multiple myeloma.

After a solid but modest launch in acute lymphoblastic leukemia, Autolus sees an opportunity for its CAR-T in autoimmune disease, starting with lupus nephritis.

Novartis presented Phase III results for anti-BAFF/ADCC antibody ianalumab in the second-line treatment of immune thrombocytopenia but will wait for first-line data to file for approvals in 2027.

Next-gen CAR-T therapies showcased at the American Society of Hematology's annual meeting promise improved efficacy and safety, with Novartis, Gilead, and Kelonia advancing pivotal trials and exploring in vivo approaches.

The company presented data on four patients as a late-breaking abstract at the American Society of Hematology meeting.

Data from the Phase III BRUIN CLL-313 trial presented at ASH showed clear superiority for the non-covalent BTK inhibitor as a single agent compared with bendamustine/rituximab.

InnoCare talks to Scrip about the plans and potential benefits for its BCL2 inhibitor mesutoclax in mantle cell lymphoma and beyond as it presents new results at ASH, as BeOne’s contender sonrontoclax also moves ahead in the same indication.

The Polish biotech says that data presented at the Orlando meeting also strengthens its confidence in the CDK8/19 inhibitor's potential across hematologic cancers with limited treatment options.

The base-editing company’s risto-cel may have an efficacy edge over Vertex’s Casgevy, but both will be held back by safety concerns about chemotherapy preconditioning for patients.

The Watertown, MA-based biotech is set for a pivotal year, with multiple catalysts expected in 2026, including full data from a Phase II trial it previewed at ASH 2025.

The company presented positive efficacy and safety data from its registrational Phase II iMMagine-1 trial at the 2025 ASH meeting.

The company presented Phase II results at ASH that lend support to an ongoing Phase III trial of the CELMoD drug in maintenance therapy of multiple myeloma.

The biotech will present data at the upcoming ASH meeting on three patients who achieved PRs or VGPRs with minimal residual disease negativity and no cases of neurotoxicity.

Following promising Phase II data presented at ASH on the company's allogenic leukemia-derived dendritic cell vaccine, Mendus has secured support from the FDA and the EMA for pivotal studies starting later this year.

Data presented at the ASH conference showed high overall response and complete response rates in heavily pretreated CLL patients with Epkinly.

With two products on the market, a third on the way and a fourth under development too, the question becomes how they will fit in relative to each other and also CAR-T cell therapies.

BMS presented Phase I/II data for its next-generation small molecule drugs mezigdomide and iberdomide at ASH.